SEARCH

SEARCH BY CITATION

8.5 References

  • 1
    Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteraemia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 10821085.
  • 2
    Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982–1993 [corrected]. Arch Pathol Lab Med 1994; 118: 884890.
  • 3
    Mocroft A, Katlama C, Johnson AM et al. AIDS Across Europe 1994–98: the EuroSIDA study. Lancet 2000; 356: 291296.
  • 4
    Race EM, Adelson-Mitty J, Kriegel GR et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252255.
  • 5
    Aberg JA, Chin-Hong PV, McCutchan A, Koletar SL, Currier JS. Localized osteomyelitis due to Mycobacterium avium complex in patients with human immunodeficiency virus receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 35: E8E13.
  • 6
    Nyberg DA, Federle MP, Jeffrey RB, Bottles K, Wofsy CB. Abdominal CT findings of disseminated Mycobacterium avium-intracellulare in AIDS. Am J Roentgenol 1985; 145: 297299.
  • 7
    Chin DP, Hopewell PC, Yajko DM et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169: 289295.
  • 8
    French MA, Lenzo N, John M et al. Immune restoration disease after treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Medicine 2000; 1: 107115.
  • 9
    Thaker H, Ong EL. Localized Mycobacterium avium complex in a patient on HAART. Clin Microbiol Infect 2000; 6: 564566.
  • 10
    Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 122128.
  • 11
    Hawkins CC, Gold JW, Whimbey E et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184188.
  • 12
    Wallace JM, Hannah JB. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. A clinicopathologic study. Chest 1988; 93: 926932.
  • 13
    Yagupsky P, Menegus MA. Cumulative positivity rates of multiple blood cultures for Mycobacterium avium-intracellulare and Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1990; 114: 923925.
  • 14
    Reves R, Stone-Venohr B, Hildred G, Kane S, Cohn D. Utility of paired blood cultures in the diagnosis of disseminated Mycobacterium avium complex infection. Int Conf AIDS 1992; 8: 127. Abstract PuB 7468.
  • 15
    Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium avium-intracellulare from blood of patients with AIDS. J Clin Pathol 1988; 41: 687690.
  • 16
    Kiehn TE, Edwards FF. Rapid identification using a specific DNA probe of Mycobacterium avium complex from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1987; 25: 15511552.
  • 17
    Cousins D, Francis B, Dawson D. Multiplex PCR provides a low-cost alternative to DNA probe methods for rapid identification of Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol 1996; 34: 23312333.
  • 18
    Nichols L, Florentine B, Lewis W, Sattler F, Rarick MU, Brynes RK. Bone marrow examination for the diagnosis of mycobacterial and fungal infections in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1991; 115: 11251132.
  • 19
    Northfelt DW, Mayer A, Kaplan LD et al. The usefulness of diagnostic bone marrow examination in patients with human immunodeficiency virus (HIV) infection. J Acquir Immune Defic Syndr 1991; 4: 659666.
  • 20
    Shafran SD, Singer J, Zarowny DP et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377383.
  • 21
    Chaisson RE, Benson CA, Dube MP et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121: 905911.
  • 22
    Dunne M, Fessel J, Kumar P et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000; 31: 12451252.
  • 23
    Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998; 27: 12781285.
  • 24
    Koletar SL, Berry AJ, Cynamon M et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob Agents Chemother 1999; 43: 28692872.
  • 25
    Cohn DL, Fisher EJ, Peng GT et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 1999; 29: 125133.
  • 26
    May T, Brel F, Beuscart C et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 1997; 25: 621629.
  • 27
    Dube MP, Sattler FR, Torriani FJ et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997; 176: 12251232.
  • 28
    Gordin FM, Sullam PM, Shafran SD et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28: 10801085.
  • 29
    Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immune deficiency syndrome. Clin Infect Dis 2003; 37: 12341243.
  • 30
    Shafran SD, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. N Engl J Med 1994; 330: 438439.
  • 31
    Hafner R, Bethel J, Power M et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42: 631639.
  • 32
    Shafran SD, Singer J, Zarowny DP et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998; 177: 252255.
  • 33
    Chiu J, Nussbaum J, Bozzette S et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113: 358361.
  • 34
    Chaisson RE, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311317.
  • 35
    Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
  • 36
    Aberg JA, Williams PL, Liu T et al. AIDS Clinical Trial Group 393 Study Team. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex. J Infect Dis 2003; 187: 10461052.
  • 37
    Zeller V, Truffot C, Agher R et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34: 662667.
  • 38
    Rossi M, Flepp M, Telenti A et al. Swiss HIV Cohort Study Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med Wkly 2001; 131: 471477.
  • 39
    Kirk O, Reiss P, Uberti-Foppa C et al. European HIV Cohorts. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239250.
  • 40
    Heifets L, Lindholm-Levy P, Libonati JP et al. Radiometric broth macrodilution method for determination of minimal inhibitory concentrations (MIC) with Mycobacterium avium complex isolates: proposed guidelines. Denver, CO: National Jewish Center for Immunology and Respiratory Medicine, 1993.
  • 41
    Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37: 23642370.
  • 42
    Dubé MP, Torriani FJ, See D et al. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. Clin Infect Dis 1999; 28: 136138.
  • 43
    Kemper CA, Bermudez L, Deresinski S. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1998; 177: 914920.
  • 44
    Holland SM, Eisenstein DM, Kuhns DB et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330: 13481355.
  • 45
    Havlir DV, Dube MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335: 392398.
  • 46
    Pierce M, Crampton S, Henry D et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384391.
  • 47
    El-Sadr WM, Burman WJ, Grant LB et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342: 10851092.
  • 48
    Currier JS, Williams PL, Koletar SL et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133: 493503.
  • 49
    Phillips P, Kwiatkowski MB, Copland M et al. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 122128.
  • 50
    Foudraine NA, Hovenkamp E, Notermans DW et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13: 177184.
  • 51
    Murray R, Mallal S, Heath C, French M. Cerebral Mycobacterium avium infection in an HIV- infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001; 20: 199201.
  • 52
    Aberg JA, Chin-Hong PV, McCutchan A et al. Localized osteomyelitis due to Mycobacterium avium complex in patients with human immunodeficiency virus receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 35: E8E13.
  • 53
    Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38: 11591166.
  • 54
    Palacio C, Wilker S, Stanciu S. Patient with disseminated Mycobacterium avium-intracellulare complex involving the bone marrow, causing pancytopenia. South Med J 2005; 98: 129130.
  • 55
    Pires A, Nelson M, Pozniak AL et al. Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines 2005; 3: 7.
  • 56
    Lipman MC, Carding SK. Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS 2007; 21: 383384.
  • 57
    Hardwick C, White D, Morris E, Monteiro EF, Breen RA, Lipman M. Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006; 82: 513514.
  • 58
    Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 47.
  • 59
    Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 12331238.
  • 60
    Levine B, Chaisson RE. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114: 861868.
  • 61
    Witzig RS, Fazal BA, Mera RM et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995; 21: 7785.
  • 62
    Bloch KC, Zwerling L, Pletcher MJ et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698704.
  • 63
    Griffith DE, Aksamit T, Brown-Elliott BA et al. on behalf of the ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculosis mycobacterial diseases. Am J Resp Crit Care Med 2007 175: 367416.